Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immunogenicity Assessment of a 14-Valent Human Papillomavirus Vaccine Candidate in Mice

8 Nov 2024

Abstract excerpt

Background: Cervical cancer ranks as the fourth most common cancer affecting women globally, with HPV as the primary etiology agent. Prophylactic HPV vaccines have substantially reduced the incidence of cervical cancer. Methods: This study assessed the immunogenicity of SCT1000, a 14-valent recombinant virus-like particle (VLP) vaccine developed by Sinocelltech, Ltd. using pseudovirion-based neutralization assays...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cervical Cancer and HPV Research
Share to Endometrial and Cervical Cancer Treatments
Share to Immunotherapy and Immune Responses

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39591165
DOI: 10.3390/vaccines12111262

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immunogenicity Assessment of a 14-Valent Human Papillomavirus Vaccine Candidate in MicePMID 39591165Read ↗

Generation of Monoclonal Antibodies and Development of Sandwich ELISA for 9-valent HPV VaccinesSemantic proximity Read ↗

Cervarix™ – a bivalent L1 virus-like particle vaccine for prevention of human papillomavirus type 16- and 18-associated cervical cancerSemantic proximity Read ↗

Neutralization of Human Papillomavirus (HPV) Pseudovirions: A Novel and Efficient Approach to Detect and Characterize HPV Neutralizing AntibodiesSemantic proximity Read ↗

Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18Semantic proximity Read ↗

Virus-like Particle-Based L2 Vaccines against HPVs: Where Are We Today?Semantic proximity Read ↗

A Pan-HPV Vaccine Based on Bacteriophage PP7 VLPs Displaying Broadly Cross-Neutralizing Epitopes from the HPV Minor Capsid Protein, L2Semantic proximity Read ↗

Functional assessment and structural basis of antibody binding to human papillomavirus capsidSemantic proximity Read ↗

Development of Virus-Like Particle Technology from Small Highly Symmetric to Large Complex Virus-Like Particle StructuresSemantic proximity Read ↗

RG1-VLP and Other L2-Based, Broad-Spectrum HPV Vaccine CandidatesSemantic proximity Read ↗

Validation of A Triple-color Pseudovirion-based Neutralization Assay for Immunogenicity Assessment of A 14-valent Recombinant Human Papillomavirus VaccineSemantic proximity Read ↗

Progress in L2-Based Prophylactic Vaccine Development for Protection against Diverse Human Papillomavirus Genotypes and Associated DiseasesSemantic proximity Read ↗

A Human Papillomavirus (HPV) <i>In Vitro</i> Neutralization Assay That Recapitulates the <i>In Vitro</i> Process of Infection Provides a Sensitive Measure of HPV L2 Infection-Inhibiting AntibodiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.